Oxford Biodynamics PLC (LON:OBD) Director of Business Development and Head of Statistics Dr Ewan Hunter caught up with DirectorsTalk for an exclusive interview to discuss the recent published study in..
Recent studies have highlighted super-enhancers (SEs) as important regulatory elements for gene expression, but their intrinsic properties remain incompletely characterized. Through an integrative analysis of Hi-C and ChIP-seq data, here..
There is a good understanding of the functional impact of protein-coding variants owing to historical studies of Mendelian disorders, the predictable consequences of amino acid changes and the recent availability..
Oxford Biodynamics Plc (LON:OBD) Director of Business Development & Head of Statistics Dr. Ewan Hunter talks to DirectorsTalk about the publication of a paper in the Journal of Translational Medicine...
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is..
Oxford Biodynamics PLC (LON:OBD) Chief Scientific Officer Dr Alexandre Akoulitchev caught up with DirectorsTalk for an exclusive interview to discuss their latest ALS biomarker data Q1: The latest results..
Oxford BioDynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev explains to DirectorsTalk how and why its aligned itself with the ALS field, how its biomarker work will help with more successes..
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has..
